MA27027A1 - Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes - Google Patents

Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes

Info

Publication number
MA27027A1
MA27027A1 MA27408A MA27408A MA27027A1 MA 27027 A1 MA27027 A1 MA 27027A1 MA 27408 A MA27408 A MA 27408A MA 27408 A MA27408 A MA 27408A MA 27027 A1 MA27027 A1 MA 27027A1
Authority
MA
Morocco
Prior art keywords
treatment
pde4 inhibitor
obstructive airway
anticholinergic agent
airway diseases
Prior art date
Application number
MA27408A
Other languages
English (en)
Inventor
Michael Yeadon
John W Watson
Roisin A Armstrong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129396A external-priority patent/GB0129396D0/en
Priority claimed from GB0210240A external-priority patent/GB0210240D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27027A1 publication Critical patent/MA27027A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA27408A 2001-05-25 2003-11-20 Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes MA27027A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29360601P 2001-05-25 2001-05-25
GB0129396A GB0129396D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination
GB0210240A GB0210240D0 (en) 2002-05-03 2002-05-03 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
MA27027A1 true MA27027A1 (fr) 2004-12-20

Family

ID=27256347

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27408A MA27027A1 (fr) 2001-05-25 2003-11-20 Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes

Country Status (25)

Country Link
US (1) US20040147544A1 (fr)
EP (1) EP1395288A1 (fr)
JP (1) JP2005508861A (fr)
KR (1) KR20040007605A (fr)
CN (1) CN1511042A (fr)
AP (1) AP2003002909A0 (fr)
BG (1) BG108382A (fr)
BR (1) BR0209992A (fr)
CA (1) CA2446613A1 (fr)
CO (1) CO5640041A2 (fr)
CR (1) CR7152A (fr)
CZ (1) CZ20033150A3 (fr)
EE (1) EE200300585A (fr)
HU (1) HUP0400037A2 (fr)
IL (1) IL158776A0 (fr)
MA (1) MA27027A1 (fr)
MX (1) MXPA03010162A (fr)
NO (1) NO20035204D0 (fr)
NZ (1) NZ529335A (fr)
OA (1) OA12610A (fr)
PA (1) PA8546001A1 (fr)
PL (1) PL367085A1 (fr)
SK (1) SK14312003A3 (fr)
TN (1) TNSN03123A1 (fr)
WO (1) WO2002096463A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CA2519679C (fr) * 2003-03-28 2012-08-28 Altana Pharma Ag Combinaison a effet synergique comprenant le roflumilast et un agent anticholinergique choisi parmi l'ipratropium, l'oxitropium et le tiotropium sous forme saline pour le traitement de maladies respiratoires
WO2004084897A1 (fr) * 2003-03-28 2004-10-07 Altana Pharma Ag Association synergique contenant du roflumilast et un agent anticholinergique selectionne parmi les sels d'ipratropium, d'oxitropium et de tiotropium et destinee au traitement de maladies respiratoires
CA2551780C (fr) 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg Combinaison d'anticholinergiques et de glucocorticoides pour le traitement prolonge de l'asthme et des broncho-pneumopathies chroniques obstructives
WO2005074983A2 (fr) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Traitement de la rhinite avec des anticholinergiques seuls ou combines a des antihistaminiques, des inhibiteurs de phosphodiesterase 4, ou des corticosteroides
WO2005074982A2 (fr) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combinaison d'anticholinergiques et d'inhibiteurs de phosphodiesterase type 4 pour le traitement de maladies respiratoires
WO2005102344A1 (fr) * 2004-04-27 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. Composition pharmaceutique
EP1634595B1 (fr) * 2004-08-19 2008-08-13 Rottapharm S.p.A. Utilisation de dérivés de n-phenylbenzamide pour le traitement de la bronchopneumopathie chronique obstructive
CN101128196B (zh) 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
KR100696432B1 (ko) * 2005-08-31 2007-03-19 김용환 건강진단용 팬티
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
RU2465915C2 (ru) 2005-12-21 2012-11-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных заболеваний
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552407A (en) * 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
ES2172583T3 (es) * 1995-06-06 2002-10-01 Pfizer 5,6-dihidro-9h-pirazol(3,4-c)-1,2,4-triazol(4,3-alfa)piridinas triciclicas.
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors

Also Published As

Publication number Publication date
CN1511042A (zh) 2004-07-07
JP2005508861A (ja) 2005-04-07
CR7152A (es) 2004-02-23
PL367085A1 (en) 2005-02-21
CO5640041A2 (es) 2006-05-31
TNSN03123A1 (fr) 2005-12-23
MXPA03010162A (es) 2004-03-10
OA12610A (en) 2006-06-09
BG108382A (bg) 2004-12-30
EE200300585A (et) 2004-04-15
NZ529335A (en) 2005-09-30
US20040147544A1 (en) 2004-07-29
BR0209992A (pt) 2004-04-06
PA8546001A1 (es) 2003-12-30
CZ20033150A3 (cs) 2004-06-16
AP2003002909A0 (en) 2003-12-31
NO20035204D0 (no) 2003-11-24
WO2002096463A1 (fr) 2002-12-05
CA2446613A1 (fr) 2002-12-05
SK14312003A3 (sk) 2004-08-03
IL158776A0 (en) 2004-05-12
EP1395288A1 (fr) 2004-03-10
KR20040007605A (ko) 2004-01-24
HUP0400037A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
EP1392292A4 (fr) Pyranoindazoles et leur utilisation dans le traitement du glaucome
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
MA27028A1 (fr) Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
MXPA04000793A (es) Novedoso metodo terapeutico.
MA26951A1 (fr) Derives de pyrazole pour le traitement de maladies virales
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
SI1432701T1 (sl) Uporaba heterociklicnih spojin pri zdravljenju bolezni urinarnega trakta
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
EP1463527A4 (fr) Utilisation de gammaglobuline pour le traitement de maladies d'origine immunologique
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
DK1458399T3 (da) Pregnansteroider til brug i behandlingen af CNS-sygdomme
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
HUP0400222A3 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
EP1455780A4 (fr) Nouveaux derives de benzodifurane imidazoline et de benzofurane imidazoline et leur utilisation pour traiter le glaucome
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
GB0507998D0 (en) Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
HUP0103017A3 (en) Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use
MA26908A1 (fr) S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires
EE200300505A (et) Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression